The COVID-19 pandemic has highlighted significant vulnerabilities in the pharmaceutical supply chain within European Union member states, prompting concerns about potential shortages of critical medications. Many countries in the EU were heavily reliant on pharmaceutical products imported from other countries, particularly China and India, which led to disruptions in the supply chain when borders were closed and shipping routes were impacted by the pandemic.
As a result of these shortages, there have been widespread calls for increased domestic manufacturing of pharmaceutical products within EU member states. The need for more home-manufactured pharmaceuticals has become a pressing issue, as it is essential to ensure the continued availability of essential medications during times of crisis.
The pandemic has served as a wake-up call for EU governments and policymakers, highlighting the importance of building more resilient and self-sufficient pharmaceutical supply chains. In addition to safeguarding the availability of medications during emergencies, increasing domestic pharmaceutical production would also create jobs and boost the economy within EU member states.
In response to these concerns, there have been discussions at the EU level about the need to promote and support the manufacturing of pharmaceutical products within the bloc. This includes incentivizing companies to invest in domestic production facilities and reducing regulatory barriers to manufacturing pharmaceuticals within the EU.
Overall, the pandemic has underscored the importance of ensuring a reliable and secure supply of pharmaceuticals within the EU. By promoting domestic manufacturing of pharmaceutical products, EU member states can better protect public health and ensure access to essential medications during times of crisis.
Source
Photo credit www.euronews.com
